THREE YEARS OF ENTECAVIR (ETV) RE-TREATMENT OF HBEAG(-) ETV PATIENTS WHO PREVIOUSLY DISCONTINUED ETV TREATMENT: RESULTS FROM STUDY ETV-901

被引：0
|
作者：
Shouval, Daniel [1 ]
Lai, Ching-Lung [2 ]
Chang, Ting-Tsung [3 ]
Gadano, Adrian [4 ]
Wu, Shun-Sheng [5 ]
Halota, Waldemar [6 ]
Sievert, William [7 ]
Tsai, Naoky C. S. C. [8 ]
Zhang, Hui [9 ]
Iloeje, Uchenna [9 ]
机构：
[1] Hadassah Med Org, Liver Unit, Jerusalem, Israel
[2] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[3] Natl Cheng Kung Univ, Coll Med, Dept Internal Med, Tainan 70101, Taiwan
[4] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[5] Changhua Christian Hosp, Dept Internal Med, Changhua, Taiwan
[6] Klin Chorob Zakaznych AM, Bydgoszcz, Poland
[7] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia
[8] Univ Hawaii, Honolulu, HI 96822 USA
[9] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA
来源：
HEPATOLOGY | 2008年 / 48卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
927
引用
收藏
页码：722A / 723A
页数：2
相关论文
共 50 条
  • [1] 3 years of ETV re-treatment in HBeAg (-) patients who previously discontinued ETV treatment: results from study ETV-901
    Sievert, W.
    Shouval, D.
    Lai, C.
    Chang, T. T.
    Gadano, A.
    Wu, S.
    Halota, W.
    Tsai, N. C.
    Zhang, H.
    Iloeje, U.
    Munafo, L.
    Newman, J.
    Slade, P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A273 - A273
  • [2] ETV re-treatment of nucleoside-naive HBeAG(-) patients
    Senturk, H.
    Lurie, Y.
    Gadano, A.
    Tan, C. K.
    Tran, T.
    Lee, S. D.
    Tsai, N.
    Cheinquer, H.
    Yang, J.
    Tamez, R.
    Hindes, R.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S197 - S197
  • [3] FIVE YEARS OF CONTINUOUS ENTECAVIR FOR NUCLEOSIDE-NAiVE HBEAG(+) CHRONIC HEPATITIS B: RESULTS FROM STUDY ETV-901
    Han, Steven-Huy B.
    Chang, Ting-Tsung
    Chao, You-Chen
    Yoon, Seung Kew
    Gish, Robert G.
    Cheinquer, Hugo
    Kitis, George E.
    Zhang, Hui
    Iloeje, Uchenna
    HEPATOLOGY, 2008, 48 (04) : 705A - 706A
  • [4] Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Manns, M.
    Shouval, D.
    Akarca, U. S.
    Hatzis, G.
    Kitis, G.
    Zink, R.
    Zhu, J.
    Brett-Smith, H.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S86 - S86
  • [5] Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027)
    Akarca, U.
    Hatzis, G.
    Kitis, G.
    Shouval, D.
    Lai, C.
    Cheinquer, H.
    Chang, T.
    Zink, R.
    Zhu, J.
    Brett-Smith, H.
    LIVER INTERNATIONAL, 2006, 26 : 5 - 5
  • [6] Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901)
    Chang, Ting-Tsung
    Chao, You-Chen
    Kaymakoglu, Sabahattin
    Cheinquer, Hugo
    Pessoa, Mario
    Gish, Robert
    Poordad, Fred
    Yang, Joanna
    Brett-Smith, Helena
    Hindes, Robert
    HEPATOLOGY, 2006, 44 (04) : 229A - 229A
  • [7] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    De Man, R. A.
    Mutimer, D.
    Gish, R.
    Chang, T.
    Zhu, J.
    Cross, A.
    Brett-Smith, H.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S89 - S89
  • [8] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Sollano, J.
    De Man, R. A.
    Mutimer, D.
    Gish, R. G.
    Chang, T. -T.
    Zhu, J.
    Cross, A.
    Brett-Smith, H.
    LIVER INTERNATIONAL, 2006, 26 : 6 - 7
  • [9] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Chang, Ting-Tsung
    Chao, You-Chen
    Sollano, Jose
    Han, Kwang-Hyub
    Lai, Ching-Lung
    Lao-Tan, Judy
    Akbar, Nurul
    Zhu, Jin
    Cross, Anne
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A33 - A33
  • [10] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Chang, Ting-Tsung
    Chao, You-Chen
    Sollano, Jose
    Han, Kwang-Hyub
    Lai, Ching-Lung
    Lao-Tan, Judy
    Akbar, Nurul
    Zhu, Jin
    Cross, Anne
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A89 - A89
12345